drugset / Trial / NCT03492697

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

NCT03492697

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjects.

Timeline

Start
2018-04-30
Primary completion
2018-07-18
Completion
2018-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Danuglipron Small molecule Oral

Indications

No indication recorded.